Cerenome, Inc. (CNSY) - Net Assets
Based on the latest financial reports, Cerenome, Inc. (CNSY) has net assets worth $11.96 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.92 Million) and total liabilities ($7.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Cerenome, Inc. (CNSY) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.96 Million |
| % of Total Assets | 60.06% |
| Annual Growth Rate | -14.73% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cerenome, Inc. - Net Assets Trend (2022–2025)
This chart illustrates how Cerenome, Inc.'s net assets have evolved over time, based on quarterly financial data. See Cerenome, Inc. (CNSY) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Cerenome, Inc. (2022–2025)
The table below shows the annual net assets of Cerenome, Inc. from 2022 to 2025. For live market cap and overall valuation, see market value of Cerenome, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.00 Million | +144.65% |
| 2024-12-31 | $-8.95 Million | -563.87% |
| 2023-12-31 | $-1.35 Million | -120.92% |
| 2022-12-31 | $6.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cerenome, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4868000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $519.86 Million | 13009.53% |
| Total Equity | $4.00 Million | 100.00% |
Cerenome, Inc. Competitors by Market Cap
The table below lists competitors of Cerenome, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NBEST Prime VIII Inmuebles Socimi SA
MC:YINB8
|
$25.34 Million |
|
Helios Towers Plc
LSE:HTWS
|
$25.35 Million |
|
Vietnam Petroleum Transport JSC
VN:VIP
|
$25.36 Million |
|
Reyna Silver Corp
V:RSLV
|
$25.37 Million |
|
Woojin Plaimm
KO:049800
|
$25.33 Million |
|
SGA Solutions Co.Ltd
KQ:184230
|
$25.33 Million |
|
FSBM Holdings Bhd
KLSE:9377
|
$25.33 Million |
|
Carelabs Co.Ltd
KQ:263700
|
$25.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cerenome, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -8,949,000 to 3,996,000, a change of 12,945,000.
- Net loss of 22,386,000 reduced equity.
- New share issuances of 38,541,000 increased equity.
- Other factors decreased equity by 3,210,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.39 Million | -560.21% |
| Share Issuances | $38.54 Million | +964.49% |
| Other Changes | $-3.21 Million | -80.33% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cerenome, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 5.11x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $71.93 | $3.68 | x |
| 2023-12-31 | $-7.58 | $3.68 | x |
| 2024-12-31 | $-37.94 | $3.68 | x |
| 2025-12-31 | $0.72 | $3.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cerenome, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -560.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.09x
- Recent ROE (-560.21%) is below the historical average (-218.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -314.58% | 0.00% | 0.00x | 3.70x | $-20.92 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.18 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.08 Million |
| 2025 | -560.21% | 0.00% | 0.00x | 4.09x | $-22.79 Million |
Industry Comparison
This section compares Cerenome, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $130,642,634
- Average return on equity (ROE) among peers: -29.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cerenome, Inc. (CNSY) | $11.96 Million | -314.58% | 0.67x | $25.33 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $142.40 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.56 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $23.40 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $10.37 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $4.87 Billion |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more